Overview

A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)

Status:
Terminated
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether 2.0mg Ranibizumab is effective in the treatment of recurrent fluid.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
David M. Brown, M.D.
Collaborator:
Genentech, Inc.
Treatments:
Bevacizumab
Ranibizumab